Literature DB >> 33196982

Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin.

George Markousis-Mavrogenis1, Petros P Sfikakis2, Sophie I Mavrogeni3, Maria G Tektonidou2.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, and/or small vessel thrombosis, pregnancy morbidity, and persistently elevated levels of antiphospholipid antibodies (aPL). Cardiovascular disease (CVD) in APS can present as heart valvular disease (HVD), macro-micro-coronary artery disease (CAD), myocardial dysfunction, cardiac thrombi, or pulmonary hypertension. Brain disease presents as stroke or transient ischemic attack (TIA) and less frequently as cerebral venous thrombosis, seizures, cognitive dysfunction, multiple sclerosis (MS)-like syndrome, or chorea. Infarcts and focal white matter hyperenhancement are the commonest brain (MRI) abnormalities, while myocardial ischemia/fibrosis, valvular stenosis/regurgitation, or cardiac thrombi are the main abnormalities detected by cardiovascular magnetic resonance. This review aims to present the existing evidence on brain/heart involvement and their interrelationship in APS and the role of brain/heart MRI in their evaluation. Embolic brain disease, due to HVD, CAD, and/or cardiac thrombus, or brain hypo-perfusion, due to myocardial dysfunction, are among the main brain/heart interactions in APS and they are considered determinants of morbidity and mortality. Currently, there is no evidence to support the use of combined brain/heart MRI in asymptomatic APS patients. Until more data will be available, this approach may be considered in APS patients at high risk for CVD/stroke, such as systemic lupus erythematosus with high-risk aPL profile or high scores in CVD risk prediction models; APS patients with HVD/thrombus, CAD, or heart failure; those with classic and non-criteria neurologic APS manifestations (seizures, cognitive dysfunction, MS-like syndrome); or with aggressive multi-organ disease. Key Points • Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) can present as heart valvular disease (HVD), macro-micro-coronary artery disease (CAD), myocardial dysfunction, cardiac thrombi, or pulmonary hypertension. • Brain disease presents as stroke or transient ischemic attack (TIA), and less frequently as cerebral venous thrombosis, seizures, cognitive dysfunction, and multiple sclerosis (MS). • A combined brain/heart MRI may be considered in APS patients at high risk for CVD/stroke, such as systemic lupus erythematosus with high-risk aPL profile or high scores in CVD risks; APS patients with HVD/thrombus, CAD, or heart failure; those with classic and non-criteria neurologic APS manifestations (seizures, cognitive dysfunction, MS-like syndrome); or with aggressive multi-organ disease.

Entities:  

Keywords:  Antiphospholipid syndrome; Brain/heart magnetic resonance imaging; Cardiovascular manifestations; Central nervous system manifestations; Computed tomography; Nuclear cardiology

Mesh:

Substances:

Year:  2020        PMID: 33196982     DOI: 10.1007/s10067-020-05498-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

1.  Asherson's syndrome of the catastrophic antiphospholipid antibodies.

Authors:  Yehuda Shoenfeld; Ricard Cervera
Journal:  J Rheumatol       Date:  2008-10       Impact factor: 4.666

2.  Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Milica Kontic; Natasa Stanisavljevic; Slavica Radovanovic; Dragomir Marisavljevic
Journal:  Isr Med Assoc J       Date:  2014-03       Impact factor: 0.892

3.  Relationship between cerebrovascular and valvular manifestations in a Serbian cohort of patients with antiphospholipid syndrome.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Slavica Banicevic; Dusica Smiljanic; Branislav Milovanovic
Journal:  Clin Exp Rheumatol       Date:  2018-05-24       Impact factor: 4.473

4.  Left ventricular thrombus mimicking primary cardiac tumor in a patient with primary antiphospholipid syndrome and recurrent systemic embolism.

Authors:  Tomás F Cianciulli; María C Saccheri; Jorge A Lax; Roberto O Neme; Juan F Alvarez Sevillano; María E Maiori; Sebastian Fandino Lound; Coloma E Parisi; Horacio A Prezioso; Luis A Vidal
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

5.  Pulmonary hypertension secondary to thrombosis of the pulmonary vessels in a patient with the primary antiphospholipid syndrome.

Authors:  A Brucato; F Baudo; M Barberis; R Redaelli; G Casadei; F Allegri; E De Juli; F De Cataldo
Journal:  J Rheumatol       Date:  1994-05       Impact factor: 4.666

  5 in total
  1 in total

1.  A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome.

Authors:  Xiaodong Song; Yangyi Fan; Yuan Jia; Gongming Li; Meige Liu; Yicheng Xu; Jun Zhang; Chun Li
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.